Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
Open randomized therapeutic study to assess the efficacy of Xarelto 15mg/day in the recurrence of thromboembolic event compared to an untreated group in patients with chronic portal vein thrombosis without high risk thrombophilia.
Epistemonikos ID: f0dc971965cbde8fff11541b50c3be596e9fc09f
First added on: May 12, 2024